Benitec Biopharma (BNTC) Competitors

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Does the MarketBeat Community prefer CALT or BNTC?

Benitec Biopharma received 172 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 65.89% of users gave Benitec Biopharma an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.

Company	Underperform	Outperform
Calliditas Therapeutics AB (publ)	Outperform Votes 27 55.10%	Underperform Votes 22 44.90%
Benitec Biopharma	Outperform Votes 199 65.89%	Underperform Votes 103 34.11%

Do analysts rate CALT or BNTC?

Calliditas Therapeutics AB (publ) currently has a consensus target price of $39.25, suggesting a potential downside of 1.88%. Benitec Biopharma has a consensus target price of $24.71, suggesting a potential upside of 77.42%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Benitec Biopharma is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Benitec Biopharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.22

Does the media favor CALT or BNTC?

In the previous week, Benitec Biopharma had 13 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 13 mentions for Benitec Biopharma and 0 mentions for Calliditas Therapeutics AB (publ). Benitec Biopharma's average media sentiment score of 0.84 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Benitec Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Benitec Biopharma	Positive

Is CALT or BNTC more profitable?

Benitec Biopharma has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Benitec Biopharma's return on equity of -44.61% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Benitec Biopharma	N/A	-44.61%	-41.25%

Which has more risk and volatility, CALT or BNTC?

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Do institutionals and insiders believe in CALT or BNTC?

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 1.3% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has better valuation and earnings, CALT or BNTC?

Benitec Biopharma has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	-21.62
Benitec Biopharma	$80K	4,457.60	-$21.75M	-$1.51	-9.23

Summary

Benitec Biopharma beats Calliditas Therapeutics AB (publ) on 15 of the 19 factors compared between the two stocks.